deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02722668

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Acute Leukemia Acute Lymphoblastic Leukemia/Lymphoma Acute Myeloid Leukemia Biphenotypic/Undifferentiated/Prolymphocytic Leukemias Bone Marrow Failure Syndromes Burkitt's Lymphoma Chronic Myelogenous Leukemia Follicular Lymphoma Hodgkin Lymphoma Large-cell Lymphoma Leukemia or MDS in Aplasia Lymphoplasmacytic Lymphoma MRD Positive Leukemia Mantle-cell Lymphoma Marginal Zone B-cell Lymphoma Multiple Myeloma Myelodysplastic Syndrome Myeloproliferative Neoplasms/Myelofibrosis Natural Killer Cell Malignancies Plasma Cell Leukemia Prolymphocytic Leukemia Relapsed Chronic Lymphocytic Leukemia Relapsed Multiple Myeloma Relapsed Small Lymphocytic Lymphoma Relapsed T-Cell Lymphoma
Interventions ATG Cyclophosphamide Fludarabine MMF Sirolimus TBI Umbilical cord blood cell infusion
Updated 15 times since 2017 Last updated: Jun 18, 2025 Started: May 15, 2017 Primary completion: Feb 22, 2023 Completion: Feb 22, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Leukemia and Acute Lymphoblastic Leukemia/Lymphoma and is currently completed. Masonic Cancer Center, University of Minnesota leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Oct 2020 · 12 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  3. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Oct 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  5. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  7. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations